Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05121038 | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab(CENDIFOX) | active not recruiting | Phase 1 / Phase 2 | 50 | Anup KasiOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 |
| NCT03329248 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 6 | ImmunityBio, Inc.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03252808 | Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. | active not recruiting | Phase 1 | 36 | Takara Bio Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03086642 | Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | completed | Phase 1 | 10 | Karie D. Runcie, MDOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT01010945 | Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer | completed | Phase 1 | 19 | OSI PharmaceuticalsINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | completed | Phase 1 / Phase 2 | 47 | Lokon Pharma ABINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05784597 | A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors(FAPrimo) | completed | Phase 1 | 18 | Philogen S.p.A.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06532344 | An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer | active not recruiting | Phase 1 | 32 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05182112 | Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver | completed | Phase 1 | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT06662669 | YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Oct 29, 2024 | clinicaltrials |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors(CAR) | terminated | Phase 1 | 9 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT00630552 | QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 138 | NantCell, Inc.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 68 | OBI Pharma, IncINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT03087591 | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 11 | Wake Forest University Health SciencesOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors(PACT) | completed | Phase 1 | 164 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04098432 | STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma(CA209-9KH) | completed | Phase 1 / Phase 2 | 15 | University Hospital Hradec KraloveOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03716596 | SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients(CISPD-2) | terminated | Phase 1 | 8 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05052567 | CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma | completed | Phase 1 / Phase 2 | 50 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2024 | clinicaltrials |
| NCT03517176 | CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer | completed | Phase 1 | 30 | Lisata Therapeutics, Inc.INDUSTRY | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT04228601 | A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 39 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02024009 | Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2(SCALOP-2) | completed | Phase 1 / Phase 2 | 159 | University of OxfordOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT03819387 | A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer | completed | Phase 1 | 49 | Nitto BioPharma, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06256055 | Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors | unknown | Phase 1 | 24 | UTC Therapeutics Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06513455 | Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 132 | Harbin Medical UniversityOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT03956056 | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | terminated | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT02021604 | Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | recruiting | Phase 1 | 250 | Cook Children's Health Care SystemOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05183243 | GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results | unknown | Phase 1 | 68 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | terminated | Phase 1 | 3 | Hoffmann-La RocheINDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2024source: clinicaltrials